Is Tonix Pharmaceuticals Stock a Good Investment?
Tonix Pharmaceuticals Investment Advice | TNXP |
- Examine Tonix Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Tonix Pharmaceuticals' leadership team and their track record. Good management can help Tonix Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Tonix Pharmaceuticals' business and its evolving consumer preferences.
- Compare Tonix Pharmaceuticals' performance and market position to its competitors. Analyze how Tonix Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Tonix Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Tonix Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Tonix Pharmaceuticals Holding stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Tonix Pharmaceuticals Holding is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Insignificant | Details | |
Volatility | Unstable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Tonix Pharmaceuticals Stock
Researching Tonix Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book ratio of 1.33. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tonix Pharmaceuticals recorded a loss per share of 8039.0. The entity last dividend was issued on the 1st of November 2019. The firm had 1:100 split on the 5th of February 2025.
To determine if Tonix Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Tonix Pharmaceuticals' research are outlined below:
| Tonix Pharmaceuticals had very high historical volatility over the last 90 days | |
| Tonix Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 10.09 M. Net Loss for the year was (130.04 M) with profit before overhead, payroll, taxes, and interest of 2.34 M. | |
| Tonix Pharmaceuticals Holding currently holds about 145.48 M in cash with (60.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.38. | |
| Tonix Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to ... |
Tonix Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Tonix Pharmaceuticals Holding. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Tonix Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 11th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 11th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Tonix Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Tonix Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-13 | 2024-03-31 | -0.39 | -0.18 | 0.21 | 53 | ||
2022-08-08 | 2022-06-30 | -1.44 | -1.22 | 0.22 | 15 | ||
2023-03-13 | 2022-12-31 | -0.86 | -0.56 | 0.3 | 34 | ||
2022-03-14 | 2021-12-31 | -1.92 | -2.24 | -0.32 | 16 | ||
2022-11-07 | 2022-09-30 | -1.02 | -0.69 | 0.33 | 32 | ||
2023-11-09 | 2023-09-30 | -1.49 | -1.83 | -0.34 | 22 | ||
2021-05-10 | 2021-03-31 | -1.76 | -2.24 | -0.48 | 27 | ||
2021-11-08 | 2021-09-30 | -2.24 | -1.6 | 0.64 | 28 |
Tonix Pharmaceuticals Target Price Consensus
Tonix target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Tonix Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 2 | Strong Buy |
Most Tonix analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Tonix stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Tonix Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationTonix Pharmaceuticals Target Price Projection
Tonix Pharmaceuticals' current and average target prices are 20.17 and 5.83, respectively. The current price of Tonix Pharmaceuticals is the price at which Tonix Pharmaceuticals Holding is currently trading. On the other hand, Tonix Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Tonix Pharmaceuticals Market Quote on 28th of March 2025
Target Price
Analyst Consensus On Tonix Pharmaceuticals Target Price
Tonix Pharmaceuticals Analyst Ratings
Tonix Pharmaceuticals' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Tonix Pharmaceuticals stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Tonix Pharmaceuticals' financials, market performance, and future outlook by experienced professionals. Tonix Pharmaceuticals' historical ratings below, therefore, can serve as a valuable tool for investors.Know Tonix Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tonix Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tonix Pharmaceuticals Holding backward and forwards among themselves. Tonix Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Tonix Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Kellett Schaffner Wealth Advisors Llc | 2024-12-31 | 30 K | Ballew Advisors, Inc | 2024-12-31 | 25 K | Joseph P. Lucia & Associates, Llc | 2024-12-31 | 20 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 18.3 K | Jpmorgan Chase & Co | 2024-12-31 | 17.3 K | Lpl Financial Corp | 2024-12-31 | 15 K | Wealthcare Advisory Partners Llc | 2024-12-31 | 10 K | Mrp Capital Investments Llc | 2024-12-31 | 10 K | Sbi Securities Co Ltd | 2024-12-31 | 3.8 K | Blackrock Inc | 2024-12-31 | 5.9 M | Geode Capital Management, Llc | 2024-12-31 | 2 M |
Tonix Pharmaceuticals' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 91.01 M.Market Cap |
|
Tonix Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.80) | (0.84) | |
| Return On Capital Employed | (0.95) | (0.99) | |
| Return On Assets | (0.80) | (0.84) | |
| Return On Equity | (0.93) | (0.98) |
Determining Tonix Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Tonix Pharmaceuticals is a good buy. For example, gross profit margin measures Tonix Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Tonix Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Tonix Pharmaceuticals' management efficiency
Tonix Pharmaceuticals has return on total asset (ROA) of (0.4407) % which means that it has lost $0.4407 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3869) %, meaning that it created substantial loss on money invested by shareholders. Tonix Pharmaceuticals' management efficiency ratios could be used to measure how well Tonix Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/28/2025, Return On Tangible Assets is likely to drop to -0.84. In addition to that, Return On Capital Employed is likely to drop to -0.99. At this time, Tonix Pharmaceuticals' Total Current Liabilities is relatively stable compared to the past year. As of 03/28/2025, Liabilities And Stockholders Equity is likely to grow to about 171 M, while Non Current Liabilities Total is likely to drop slightly above 3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 189.53 | 199.01 | |
| Tangible Book Value Per Share | 189.37 | 198.83 | |
| Enterprise Value Over EBITDA | 0.93 | 0.97 | |
| Price Book Value Ratio | 0.17 | 0.18 | |
| Enterprise Value Multiple | 0.93 | 0.97 | |
| Price Fair Value | 0.17 | 0.18 | |
| Enterprise Value | -66.4 M | -63.1 M |
The management strategies employed by Tonix Pharmaceuticals' are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Beta 2.238 |
Basic technical analysis of Tonix Stock
As of the 28th of March, Tonix Pharmaceuticals has the Risk Adjusted Performance of 0.0613, coefficient of variation of 1609.01, and Semi Deviation of 13.64. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tonix Pharmaceuticals, as well as the relationship between them.Tonix Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tonix Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tonix Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tonix Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tonix Pharmaceuticals' Outstanding Corporate Bonds
Tonix Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tonix Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tonix bonds can be classified according to their maturity, which is the date when Tonix Pharmaceuticals Holding has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Tonix Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Tonix Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0613 | |||
| Market Risk Adjusted Performance | 0.2884 | |||
| Mean Deviation | 10.95 | |||
| Semi Deviation | 13.64 | |||
| Downside Deviation | 14.48 | |||
| Coefficient Of Variation | 1609.01 | |||
| Standard Deviation | 16.5 | |||
| Variance | 272.29 | |||
| Information Ratio | 0.0631 | |||
| Jensen Alpha | 1.11 | |||
| Total Risk Alpha | 1.53 | |||
| Sortino Ratio | 0.0719 | |||
| Treynor Ratio | 0.2784 | |||
| Maximum Drawdown | 110.72 | |||
| Value At Risk | (21.96) | |||
| Potential Upside | 33.49 | |||
| Downside Variance | 209.72 | |||
| Semi Variance | 186.02 | |||
| Expected Short fall | (13.04) | |||
| Skewness | 0.3698 | |||
| Kurtosis | 3.23 |
| Risk Adjusted Performance | 0.0613 | |||
| Market Risk Adjusted Performance | 0.2884 | |||
| Mean Deviation | 10.95 | |||
| Semi Deviation | 13.64 | |||
| Downside Deviation | 14.48 | |||
| Coefficient Of Variation | 1609.01 | |||
| Standard Deviation | 16.5 | |||
| Variance | 272.29 | |||
| Information Ratio | 0.0631 | |||
| Jensen Alpha | 1.11 | |||
| Total Risk Alpha | 1.53 | |||
| Sortino Ratio | 0.0719 | |||
| Treynor Ratio | 0.2784 | |||
| Maximum Drawdown | 110.72 | |||
| Value At Risk | (21.96) | |||
| Potential Upside | 33.49 | |||
| Downside Variance | 209.72 | |||
| Semi Variance | 186.02 | |||
| Expected Short fall | (13.04) | |||
| Skewness | 0.3698 | |||
| Kurtosis | 3.23 |
Consider Tonix Pharmaceuticals' intraday indicators
Tonix Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Tonix Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 528056.0 | |||
| Daily Balance Of Power | (1.35) | |||
| Rate Of Daily Change | 0.7 | |||
| Day Median Price | 22.6 | |||
| Day Typical Price | 21.79 | |||
| Price Action Indicator | (6.72) | |||
| Period Momentum Indicator | (8.59) | |||
| Relative Strength Index | 64.34 |
Tonix Pharmaceuticals Corporate Filings
8K | 24th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 21st of March 2025 Other Reports | ViewVerify | |
10K | 18th of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
F4 | 28th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Tonix Stock media impact
Far too much social signal, news, headlines, and media speculation about Tonix Pharmaceuticals that are available to investors today. That information is available publicly through Tonix media outlets and privately through word of mouth or via Tonix internal channels. However, regardless of the origin, that massive amount of Tonix data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Tonix Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Tonix Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Tonix Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Tonix Pharmaceuticals alpha.
Tonix Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Tonix Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Tonix Pharmaceuticals Historical Investor Sentiment
Investor biases related to Tonix Pharmaceuticals' public news can be used to forecast risks associated with an investment in Tonix. The trend in average sentiment can be used to explain how an investor holding Tonix can time the market purely based on public headlines and social activities around Tonix Pharmaceuticals Holding. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Tonix Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Tonix Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Tonix Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Tonix Pharmaceuticals.
Tonix Pharmaceuticals Corporate Management
| Seth MD | President, CoFounder | Profile | |
| CPA CPA | CFO Treasurer | Profile | |
| Daniel MD | Consultant | Profile | |
| Dr MBA | Executive Research | Profile | |
| Thomas MBA | Executive Operations | Profile |
Additional Tools for Tonix Stock Analysis
When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.